CD8A and bone marrow neoplasm: Donnelly et al. proved STING activator DMXAA may facilitate analgesia, partly by increasing CD8+ T cells in the microenvironment of bone marrow tumor [52], but recent research suggested that another STING agonist, ADU-S100, activated CD8+ T cells at a low dose, while high doses led to the death of the CD8+ T cells [22,59].